SC 13D/A 1 0001.txt AMENDMENT NO. 5 TO SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5) ALLTRISTA CORPORATION -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, no par value -------------------------------------------------------------------------------- (Title of Class of Securities) 020040101 -------------------------------------------------------------------------------- (CUSIP Number of Class of Securities) Marlin Partners II, L.P. Attn: Martin E. Franklin 555 Theodore Fremd Avenue, Suite B-302, Rye, NY 10580 (914)967-9400 -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Copies to: William J. Grant, Esq. Willkie Farr & Gallagher 787 Seventh Avenue New York, NY 10019 (212) 728-8000 October 10, 2000 -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Schedule) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following: [ ] SCHEDULE 13D ------------------- ----------------- CUSIP No. 020040101 Page 2 of 5 Pages ------------------- ----------------- ----------- -------------------------------------------------------------------- 1 NAME OF REPORT PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Marlin Partners II, L.P. ----------- -------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] ----------- -------------------------------------------------------------------- 3 SEC USE ONLY ----------- -------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC ----------- -------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] ----------- ------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware --------------------- --------- ------------------------------------------------ 7 SOLE VOTING POWER 575,700 --------- ------------------------------------------------ 8 SHARED VOTING POWER NUMBER OF SHARES 0 BENEFICIALLY OWNED BY --------- ------------------------------------------------ EACH 9 SOLE DISPOSITIVE POWER REPORTING PERSON WITH 575,700 --------- ------------------------------------------------ 10 SHARED DISPOSITIVE POWER 0 ----------- -------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON 575,700 ----------- -------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] ----------- -------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.13% ----------- -------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* PN ----------- -------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. 2 of 5 This Amendment No. 5 to Schedule 13D is being filed by the Reporting Person solely to report a change in the purpose for which the Reporting Person holds shares of Common Stock (as defined herein), and is being filed pursuant to Rule 13d-2 under the Securities and Exchange Act of 1934, as amended. There has been no change in the number of shares of Common Stock held by the Reporting Person since the filing of Amendment No. 4 to the Schedule 13D, dated August 15, 2000. Capitalized terms used herein and not otherwise defined herein shall have the meanings given to them in the Initial Statement. The Initial Statement is supplementally amended as set forth herein. Item 1. Security and Issuer. This Amendment No. 5 to Schedule 13D relates to shares of Common Stock, no par value (the "Common Stock"), of Alltrista Corporation, an Indiana corporation (the "Company"). This Amendment No. 5 amends the initial statement (the "Initial Statement") on Schedule 13D dated January 5, 2000, as amended. The principal executive offices of the Company are located in 5875 Castle Creek Parkway, North Drive, Suite 440, Indianapolis, Indiana 46250. Item 4. Interest in Securities of the Issuer. Item 4 of the Schedule 13D is amended by adding the following paragraphs to the end of such item: 3 of 5 By letter dated October 10, 2000, Mr. Franklin requested Thomas Clark, President of the Company, to (i) respond to questions outlined in Exhibits A, B and C to this Schedule 13D, (ii) explain what strategic options are being reviewed by the Board, (iii) invite a representative of the Reporting Person (second largest shareholder of the Company) to join the Board of the Company, and (iv) rescind or amend the Company's "poison pill". A copy of the letter setting forth the Reporting Person's requests is filed as Exhibit D to this Schedule 13D. Item 7. Material to be Filed as Exhibits. Item 7 of Schedule 13D is hereby amended by adding the following paragraph to the end of such item: EXHIBIT D Letter, dated October 10, 2000. 4 of 5 SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: October 10, 2000 MARLIN PARTNERS II, L.P. By: Marlin Management, L.L.C., its General Partner By: /s/ Martin E. Franklin ------------------------------ Name: Martin E. Franklin Title: Managing Member 5 of 5